Molecular imaging, particularly Positron Emission Tomography (PET), has revolutionised our understanding and management of neurodegenerative diseases. This chapter explores the cutting-edge applications of PET imaging in visualising key molecular pathologies associated with neurodegenerative disorders, focusing on amyloid and tau protein aggregates. We discuss the principles of PET imaging, the development of specific radiotracers, and their applications in early detection, differential diagnosis, and monitoring of diseases, such as Alzheimer's and Parkinson's. The chapter also examines the role of molecular imaging in assessing disease progression and evaluating treatment response, highlighting its potential in drug development and personalised medicine. By providing a comprehensive overview of current capabilities and future directions, this chapter underscores the transformative impact of molecular imaging in the field of neurodegenerative diseases.
Keywords: Alzheimer's disease, amyloid, tau, disease progression, early detection, Molecular imaging, neurodegenerative diseases, Parkinson's disease, PET, treatment response.
